Īrija - angļu - HPRA (Health Products Regulatory Authority)

milpharm limited - valsartan - film coated tablet - 40 milligram - angiotensin ii antagonists, plain

Īrija - angļu - HPRA (Health Products Regulatory Authority)

milpharm limited - valsartan - film coated tablet - 80 milligram - angiotensin ii antagonists, plain

Īrija - angļu - HPRA (Health Products Regulatory Authority)

milpharm limited - valsartan - film coated tablet - 160 milligram - angiotensin ii antagonists, plain

Īrija - angļu - HPRA (Health Products Regulatory Authority)

milpharm limited - valsartan - film coated tablet - 320 milligram - angiotensin ii antagonists, plain

Izraēla - angļu - Ministry of Health

dexcel pharma technologies ltd - valsartan - film coated tablets - valsartan 40 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

Izraēla - angļu - Ministry of Health

dexcel pharma technologies ltd - valsartan - film coated tablets - valsartan 80 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.for treatment of hypertension.

Izraēla - angļu - Ministry of Health

dexcel pharma technologies ltd - valsartan - film coated tablets - valsartan 160 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.for treatment of hypertension.

Īrija - angļu - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - valsartan - film-coated tablet - 80 milligram(s) - angiotensin ii antagonists, plain; valsartan

Īrija - angļu - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - valsartan - film-coated tablet - 40 milligram(s) - angiotensin ii antagonists, plain; valsartan

Īrija - angļu - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - valsartan - film-coated tablet - 160 milligram(s) - angiotensin ii antagonists, plain; valsartan